Your browser doesn't support javascript.
loading
New insights into nanomedicines for oral delivery of glucagon-like peptide-1 analogs.
Pinto, Soraia Filipa Tavares; Santos, Hélder Almeida; Sarmento, Bruno Filipe Carmelino Cardoso.
Afiliación
  • Pinto SFT; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal.
  • Santos HA; Instituto de Ciências Biomédicas Abel Salazar (ICBAS), University of Porto, Porto, Portugal.
  • Sarmento BFCC; Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
Article en En | MEDLINE | ID: mdl-38500351
ABSTRACT
Type 2 diabetes mellitus (T2DM) is a metabolic disorder that arises when the body cannot respond fully to insulin, leading to impaired glucose tolerance. Currently, the treatment embraces non-pharmacological actions (e.g., diet and exercise) co-associated with the administration of antidiabetic drugs. Metformin is the first-line treatment for T2DM; nevertheless, alternative therapeutic strategies involving glucagon-like peptide-1 (GLP-1) analogs have been explored for managing the disease. GLP-1 analogs trigger insulin secretion and suppress glucagon release in a glucose-dependent manner thereby, reducing the risk of hyperglycemia. Additionally, GLP-1 analogs have an extended plasma half-life compared to the endogenous peptide due to their high resistance to degradation by dipeptidyl peptidase-4. However, GLP-1 analogs are mainly administered via subcutaneous route, which can be inconvenient for the patients. Even considering an oral delivery approach, GLP-1 analogs are exposed to the harsh conditions of the gastrointestinal tract (GIT) and the intestinal barriers (mucus and epithelium). Hereupon, there is an unmet need to develop non-invasive oral transmucosal drug delivery strategies, such as the incorporation of GLP-1 analogs into nanoplatforms, to overcome the GIT barriers. Nanotechnology has the potential to shield antidiabetic peptides against the acidic pH and enzymatic activity of the stomach. In addition, the nanoparticles can be coated and/or surface-conjugated with mucodiffusive polymers and target intestinal ligands to improve their transport through the intestinal mucus and epithelium. This review focuses on the main hurdles associated with the oral administration of GLP-1 and GLP-1 analogs, and the nanosystems developed to improve the oral bioavailability of the antidiabetic peptides. This article is categorized under Therapeutic Approaches and Drug Discovery > Nanomedicine for Infectious Disease Nanotechnology Approaches to Biology > Nanoscale Systems in Biology.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Péptido 1 Similar al Glucagón Límite: Humans Idioma: En Revista: Wiley Interdiscip Rev Nanomed Nanobiotechnol Año: 2024 Tipo del documento: Article País de afiliación: Portugal

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Péptido 1 Similar al Glucagón Límite: Humans Idioma: En Revista: Wiley Interdiscip Rev Nanomed Nanobiotechnol Año: 2024 Tipo del documento: Article País de afiliación: Portugal